调节人嗜碱性粒细胞脱颗粒
- 格式:pdf
- 大小:249.86 KB
- 文档页数:4
1 、简述补体系统的组成与主要生物学功能。
组成:①补体系统的固有成分②补体调节蛋白③补体受体功能:补体旁路途径在感染早期发挥作用,经典途径在感染中、晚期发挥作用。
①、细胞毒作用:参与宿主抗感染、抗肿瘤;②、调理作用: C3b/C4b 可作为非特异性调理素介导调理作用;③、免疫复合物清除作用:将免疫复合物随血流运输到肝脏,被吞噬细胞清除;④、炎症介质作用:C3a/C5a 的过敏毒素作用、 C5a 的趋化和激活作用、 C2a 的激肽样作用,引起炎症性充血和水肿;⑤、参与特异性免疫应答。
2 、补体激活的三个途径:经典途径:①激活物为抗原或免疫复合物, C1q 识别② C3 转化酶和 C5 转化酶分别是 C4b2a 和 C4b2a3b③其启动有赖于特异性抗体产生,故在感染后期或恢复期才能发挥作用,或参与抵御相同病原体再次感染机体旁路途径:①激活物为细菌、真菌或病毒感染细胞等,直接激活 C3② C3 转化酶和 C5 转化酶分别是 C3bBb 和 C3bBb3b③其启动无需抗体产生,故在感染早期或初次感染就能发挥作用④存在正反馈放大环MBL (凝激素)途径:①激活物非常广泛,主要是多种病原微生物表面的 N 氨基半乳糖或甘露糖,由MBL 识别②除识别机制有别于经典途径外,后续过程基本相同③其无需抗体即可激活补体,故在感染早期或对免疫个体发挥抗感染效应④对上两种途径具有交叉促进作用3 、三条补体激活途径的过程及比较:经典途径 / 旁路途径 /MBL 途径激活物:抗原抗体复合物 / 内毒素、酵母多糖、凝聚 IgA/ 病原微生物、糖类配体参与成分: C1-C9/ C3 、 C5-C9 、 B 、 D 、 P/ C2-C9 、 MBL 、 MASPC3 转化酶: C4b2a/ C3bBb/C4b 2a 、 C3bBbC5 转化酶: C4b 2a 3b/ C3bBb3b/ C4b 2a 3b 、 C3bBb3b作用:特异性免疫 / 非特异性免疫 / 非特异性免疫4 、试述补体经典激活途径的全过程。
第二十三章超敏反应性疾病及其免疫检测一、A11、关于Ⅳ型超敏反应错误的是()。
A、无明显个体差异B、发生慢C、与抗体、补体有关D、与效应T细胞和吞噬细胞及其产生的细胞因子和细胞毒性介质有关E、在抗感染免疫清除抗原的同时损伤组织2、花粉引起的支气管哮喘属于()。
A、Ⅰ型变态反应B、Ⅱ型变态反应C、Ⅲ型变态反应D、Ⅳ型变态反应E、非变态反应3、无需补体组分参与的效应是()。
A、免疫黏附B、溶解细菌C、抗B抗体与B型红细胞的溶解D、ADCCE、调理作用4、不属于Ⅲ型超敏反应性疾病的是()。
A、Arthus反应B、肾小球肾炎C、系统性红斑狼疮D、类风湿关节炎E、传染性变态反应5、迟发型超敏反应(Ⅳ型超敏反应)中最重要的细胞是()。
A、B细胞B、MΦC、Th1D、Th2E、嗜碱性粒细胞6、下列不属于Ⅰ型变态反应的是()。
A、过敏性哮喘B、过敏性鼻炎C、接触性皮炎D、过敏性胃肠炎E、荨麻疹7、为了更准确的估计患者皮试反应性,皮试时设阳性和阴性对照,阳性对照液常用()。
A、变应原的稀释保存液B、变应原提取液C、生理盐水D、二硝基氟苯E、盐酸组胺8、一种破伤风类毒素抗体(抗体1)能与发生二硫键全部断裂而变性的破伤风类毒素发生反应;另一种破伤风类毒素抗体(抗体2)不能与因同种原因变性的破伤风类毒素发生反应。
对于这一实验结果,最可能的解释是()。
A、抗体1对破伤风类毒素无特异性B、抗体2对破伤风类毒素上的构象决定簇有特异性C、抗体1对破伤风类毒素的氨基酸序列有特异性D、抗体2对二硫键有特异性E、B和C正确9、寄生虫学免疫诊断皮内试验,24小时后局部出现阳性反应属于()。
A、Ⅰ型变态反应B、Ⅱ型变态反应C、Ⅲ型变态反应D、Ⅳ型变态反应E、以上都不是10、属于Ⅰ型超敏反应的疾病是()。
A、肾小球肾炎B、风湿病C、过敏性休克D、免疫性溶血性贫血E、接触性皮炎11、对金属镍的皮肤变态反应()。
A、是由IgE介导的B、由嗜碱性粒细胞的浸润C、可用P-K试验诊断D、是由对镍和蛋白复合物致敏的T细胞引起E、可用组胺拮抗药进行有效治疗12、Ⅱ型超敏反应又称()A、速发型超敏反应B、迟发型超敏反应C、细胞毒型超敏反应D、免疫复合物型超敏反应E、Arthus反应13、可直接特异性杀伤靶细胞的是()。
天津医学综合基础知识考试试卷一、单项选择题(共23题,每题的备选项中,只有 1 个事最符合题意)1、下列物质中免疫原性最强的是A.半抗原B.多糖C.脂类D.蛋白质E.核酸2、Hageman因子的编码序号为A.FⅨB.FⅤC.FⅦD.FⅪE.FⅩ3、正常人血清中可有一定量的伤寒杆菌抗体,但一般范围在A.”0”抗体<1:40,”H”抗体<1:80B.”O”抗体<1:80,”H”抗体<1:80C.”O”抗体<1:80,”H”抗体<1:40D.”O”抗体<1:80,”H”抗体<1:160E.”O”抗体<1:40,”H”抗体<1:404、肉毒菌的感染途径是A.污染伤口B.食用污染食物C.节肢动物叮咬D.接触肉毒患者的用品E.吸入污染的空气5、”主神明”是哪一脏的功能__A.肝B.心C.脾D.肺E.肝6、面神经周围瘫的特点有()。
A.无味觉障碍。
B.不能闭眼。
C.无唾液分泌障碍。
D.不能提睑。
7、关于甲氨蝶呤,下列哪点不正确:A.用大量叶酸可减轻骨髓毒性B.抑制二氢叶酸还原酶发挥抗肿瘤作用C.可致肝肾损害D.有致畸作用E.对儿童急性白血病和绒癌疗效好8、生食不熟的猪肉可能导致A.血吸虫病B.阿米巴病C.旋毛虫病D.疟疾E.贾第虫病9、人体感染蠕形住肠线虫的主要症状为A.肠梗阻B.肛周及会阴部瘙痒C.贫血D.阴道炎、子宫内膜炎E.消化功能紊乱10、关于二尖瓣狭窄的论述错误的是A.视诊可见二尖瓣面容B.触诊心尖区常有舒张期震颤C.在心尖区可闻及低调、隆隆样、收缩中晚期杂音D.部分患者于心尖区内侧可闻及开瓣音E.中度以上狭窄心浊音界可呈梨形11、葡萄糖-6-磷酸脱氢酶缺乏者不应使用下列哪类抗菌药:A.头孢菌素类B.硝基呋喃类C.大环内酯类D.青霉素类E.多黏菌素类12、由雌激素和孕激素配伍组成的类固醇激素避孕药的优点不包括:A.月经正常,并对月经有调节作用B.可降低卵巢癌、子宫内膜癌、乳腺瘤的发病率C.高度有效D.不引起凝血功能异常E.停药后可迅速恢复生育能力13、适应性免疫应答A.吞噬细胞是主要效应细胞B.时相是在感染后数分钟至%小时C.先天获得D.具有特异性E.可遗传14、肺炎链球菌的致病力主要取决于A.内毒素B.鞭毛C.毒素D.荚膜E.过敏反应15、对尿渗量影响最大的物质是A.肌酐B.氯化钠C.蛋白质D.尿素氮E.葡萄糖16、麻醉中应用低温的主要目的是()。
肥大细胞和嗜碱性粒细胞系在过敏性疾病中的研究进展①刘庆梅②杨永仕刘艳②刘光明②孙劲旅③(变态过敏反应科,疑难重症及罕见病国家重点实验室,北京协和医院,中国医学科学院北京协和医学院,北京 100730)中图分类号R392.8 文献标志码 A 文章编号1000-484X(2023)12-2631-07[摘要]过敏性疾病的发病率越来越高,过敏原检测、疾病诊断和治疗等相关研究均离不开合适的效应细胞系。
本文针对过敏性疾病的主要效应细胞(肥大细胞和嗜碱性粒细胞)现有细胞系的基本特征进行了综述,并关注效应细胞系在过敏性疾病研究中的应用,以期为过敏性疾病的诊断和治疗研究提供理论依据。
[关键词]过敏性疾病;肥大细胞;嗜碱性粒细胞Research progress on mast cells and basophils lines in allergic diseasesLIU Qingmei, YANG Yongshi, LIU Yan, LIU Guangming, SUN Jinlyu. Allergy Department, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China[Abstract]The incidence of allergic diseases has been increasing year by year worldwide. The research of allergen detection,diagnosis of allergic diseases, as well as its prevention and treatment are inseparable from suitable effector cell lines. The current arti⁃cle highlights the basic characteristics of main effector cell lines for allergic diseases (mast cells and basophils), and focuses on the applications of effector cell lines in allergic diseases. The present review aimed to lay the foundation for the research on diagnosis and treatment for allergic diseases.[Key words]Allergic diseases;Mast cell;Basophil全球范围内受过敏性疾病困扰的人群愈来愈多,世界卫生组织将过敏性疾病列为21世纪重点防治的三大疾病之一,是当前世界性的重大卫生学问题[1-2]。
简述细胞脱颗粒现象细胞脱颗粒,这听起来像个很高大上的名词,其实它就像是细胞的一个“派对”,里面有好多小东西在欢快地跳舞,突然之间,有些小家伙就决定要离开这个派对,跑去做其他事情了。
想象一下,一个聚会中,大家都很开心,但总有那么几个小伙伴觉得“我想出去透透气”。
所以它们就悄悄地溜了出去,这就是细胞脱颗粒的一个简化版的形象。
细胞脱颗粒主要发生在一些特定的细胞里,比如说嗜碱性粒细胞、肥大细胞等。
这些细胞里藏着许多小颗粒,里面装着各种各样的“宝贝”,比如说生物活性物质。
就像是在一个神秘的仓库,里面的货物可是价值连城的。
细胞要是感觉到有威胁,比如说有病菌、过敏原等,就会迅速启动这个脱颗粒的“模式”,把这些“宝贝”释放出去。
哇,简直就像是打开了宝箱,瞬间把珍贵的财宝撒了出来,让外面的世界都沸腾了。
再说说这个过程,它是怎么发生的呢?想象一下,你在聚会上,突然有个朋友兴奋地说:“哎,我有个秘密武器要给大家看!”那一刻,整个房间的气氛都变了。
细胞也是一样,当它感受到某种刺激,就像是被点燃的火花,马上就准备“脱颗粒”了。
细胞膜的结构会发生变化,像是撩起了窗帘,让里面的颗粒一股脑儿地冲了出去。
这个过程快速而又神秘,细胞就像个魔术师,把看似平常的颗粒变成了强大的武器,保护自己。
然后,脱颗粒释放出来的东西可不简单。
这些物质会在体内发挥各种作用,像是信号弹一样,告诉周围的细胞:“快来帮忙,这里有麻烦了!”有的可能会让血管扩张,增加血流量,增强免疫反应;有的则会吸引其他细胞到达现场,形成强大的防线。
就像是一场战斗,所有细胞都团结一致,准备迎接挑战。
让人想起一句话,团结就是力量嘛!不过,细胞脱颗粒并不是单纯的“出门”。
这中间还有很多小插曲。
释放的物质也会搞得周围的环境一片混乱,比如过敏反应。
这就像是有人在派对上喝多了,结果闹了个天翻地覆,留下大家一脸懵逼。
细胞们一时兴起,释放过多的颗粒,结果就导致了炎症反应,真是让人哭笑不得。
嗜碱性粒细胞活化试验在过敏性疾病应用中的研究进展①张敏崔振泽李悦②徐超(大连市儿童医院,大连116000)中图分类号R392.8文献标志码A文章编号1000-484X(2021)22-2803-07[摘要]21世纪以来,过敏性疾病的发病率逐年增高,严重威胁着人类的生命健康。
然而临床中针对这一类疾病目前没有安全高效的检测方法。
本文通过梳理过敏性疾病及嗜碱性粒细胞活化试验的相关文献资料,认为该试验是一种安全高效的辅助诊断过敏性疾病的方法,其理论依据是嗜碱性粒细胞的表面标志物会随着过敏反应的发生而变化。
基于这一理论依据,传统的嗜碱性粒细胞活化试验是利用流式细胞术对细胞进行检测,进而体外辅助诊断过敏性疾病。
近年来基于微流体技术的新型嗜碱性粒细胞活化试验逐步兴起。
流式细胞术是一种对细胞进行快速定量分析和筛选的方法。
微流体技术是一种高精度处理小体积流体的技术,具有成本低、操作简便且所需样本及试剂量少的优点。
本文就嗜碱性粒细胞的相关概念、分别基于流式细胞术及微流体技术的嗜碱性粒细胞活化试验及其在临床过敏性疾病中的应用价值做一综述,以期为嗜碱性粒细胞活化试验在过敏性疾病诊断领域的应用提供理论支持。
[关键词]嗜碱性粒细胞;流式细胞术;微流体技术;嗜碱性粒细胞活化试验;过敏性疾病Research progress of basophil activation test and its application in allergic diseasesZHANG Min,CUI Zhen-Ze,LI Yue,XU Chao.Dalian Children's Hospital,Dalian116000,China [Abstract]Since the21st Century,the incidence rate of allergic diseases has increased year by year,which seriously threatens human life and health.However,there is no safe and efficient detection method for this kind of disease.Many literatures about allergic diseases and basophil activation test have reported that basophil activation test is a safe and efficient method for the diagnosis of allergic diseases.And the theoretical basis of this test is that the surface markers of basophils will change with the occurrence of allergic reactions.Based on this theoretical basis,the traditional basophil activation test is to detect cells by flow cytometry,and then assist in the diagnosis of allergic diseases in vitro.In recent years,a new type of basophil activation test based on microfluidic technology has been developed.Flow cytometry is a rapid method for quantitative analysis and screening of cells.Microfluidic technology is a high pre‐cision technology for processing small volume fluid,which has the advantages of low cost,simple operation and small amount of sam‐ples and reagents.In this paper,the related concepts of basophils,basophil activation test which based on flow cytometry and microflu‐idic technology,and its application value in the diagnosis of allergic diseases are reviewed in order to provide theoretical support for the application of basophil activation test in the field of allergic diseases diagnosis.[Key words]Basophil;Flow cytometry;Microfluidic technology;Basophil activation test;Allergic diseases虽然世界医疗水平、工业发展程度以及感染性疾病的防治水平不断提高,但是过敏性疾病的发病率却在全球呈现增高的趋势,严重影响公共健康,已成为21世纪需着重研究和防治的疾病之一[1]。
1.简述固有性免疫和适应性免疫的概念及作用。
答:固有性免疫是个体出生时就具有的天然免疫,通过遗传获得,是机体在长期进化过程中逐渐建立起来的非特异抵御病原体入侵的第一道防线;作用:在感染早期,产生一定的免疫应答,包括皮肤、黏膜物理屏障作用以及局部细胞分泌杀菌物质的化学效应,有非特异性效应细胞对病毒感染细胞进行杀伤,及血液和体液中效应分子的生物学作用。
适应性免疫是个体出生后,受到外来异物刺激后逐渐建立起来的后天免疫,针对某一特定的异物抗原产生特异性免疫应答。
作用:经识别抗原成分后开始分化增殖的T、B细胞产生免疫应答,经一段时间后生成效应细胞,杀伤清除病原体,起主导作用。
2.简述免疫系统具有双重功能(防卫、致病)的理论基础。
答:免疫系统通过对“自己”或“非己”抗原性异物的识别和应答,来维持自身稳定和平衡。
免疫系统在免疫功能正常条件下,对非己抗原产生排异效应,对自身抗原成分产生不应答状态,对机体正常运行具有一定的防卫作用;但当免疫功能失调时,免疫应答可造成机体组织损伤,例如免疫应答反应水平过高或过低,或者对自身组织细胞产生免疫应答,调节功能发生紊乱,这就导致免疫性相关疾病的发生。
3.简述BCR多样性产生的机制。
答:BCR(B细胞抗原受体)是通过其V区抗原结合部位来识别抗原的,BCR的V区,尤其是V区的CDR1、CDR2和CDR3氨基酸序列的多样性,决定了对抗原识别的多样性。
造成BCR 多样性的机制主要有1)组合造成的多样性:编码BCR重链V区的基因有V、D、J三种,编码轻链V区的有V和J 两种,而且每一基因又是由很多的基因片段组成。
这样,重链基因的组合和重链基因与轻链基因的组合将产生众多不同特异性的BCR。
2)连接造成的多样性:编码CDR3的基因位于轻链V、J或重链V、D、J片段的连接处,两个基因片段的连接可丢失或加入数个核苷酸,从而增加了CDR3的多样性。
3)体细胞高度突变造成的多样性:在BCR各基因片段重排完成后,其V区基因也可发生突变,而且突变频率较高,因而增加其多样性。
See discussions, stats, and author profiles for this publication at: https:///publication/262189657 Modulation Of Human Basophil Degranulation By Geranylgeranyl CompoundsArticle in Allergology International · May 2014DOI: 10.2332/allergolint.13-LE-0637 · Source: PubMedCITATIONS 0READS 147 authors, including:Masao YamaguchiTeikyo University135 PUBLICATIONS 4,204 CITATIONSSEE PROFILE Hiroyuki NagaseTeikyo University114 PUBLICATIONS 1,654 CITATIONSSEE PROFILEKen OhtaNational Hospital Organization Tokyo Nation…350 PUBLICATIONS 8,606 CITATIONSSEE PROFILEAll content following this page was uploaded by Hiroyuki Nagase on 25 August 2015.The user has requested enhancement of the downloaded file. All in-text references underlined in blue are added to the original document and are linked to publications on ResearchGate, letting you access and read them immediately.Allergology International Vol 63,Suppl 1,2014www.jsaweb.jp !49Dear EditorModulation of Human Basophil Degranulation by GeranylgeranylCompoundsRecent experimental studies have shown that the ba-sophil is critical for a subtype of anaphylaxis or IgE-mediated very late-phase skin inflammation.1Motility and activation of basophils are known to be regulated by various endogenous and !or exogenous sub-stances.The panel of known such basophil-directed molecules is expanding.One important candidate may be geranylgeranyl compounds,which were in-itially demonstrated to be protectors of the gastric mucosa.2These compounds have also demonstrated protective actions in situations that are often hazard-ous to the host.In rodent studies,geranylgeranylace-tone (GGA)suppressed the development of several inflammatory reactions and enhanced tissue regen-eration in vivo .2,3However,the effects of GGA on al-lergic effectors and immunologic reactions have not been fully clarified.In this study,we assessed the pharmacological ac-tions of GGA and related compounds on basophil de-granulation,detected as release of histamine.Baso-phils were obtained from non allergic volunteers by dextran sedimentation of whole blood.Cells were preincubated with GGA (Wako Pure Chemicals,Osaka,Japan)for 15min at 37 ,washed and then stimulated with a secretagogue for 45min.4Degranulation of basophils by polyclonal anti-IgE antibody (MBL,Nagoya,Japan )and by phorbol myristate acetate (PMA )(Sigma,St.Louis,MO,USA)was significantly enhanced by preincubation of cells for 15min with GGA at 1.4or 2.7mM (Fig.1a).Similar results were observed for highly pure baso-phils (purity >95%;prepared by Percoll gradient cen-trifugation followed by negative MACS selection),in-dicating that GGA acts directly on basophils.On the other hand,GGA showed no clear effect on basophil degranulation by a chemokine,monocyte chemoat-tractant protein (MCP)-1or Ca ionophore A23187.As shown in Figure 1b,up to 15min of incubation of ba-sophils with GGA alone at 2.7mM did not induce re-lease of histamine.However,30min or longer incuba-tion resulted in higher,15to 20%histamine release,suggesting that GGA at this concentration might damage basophils in a time-dependent manner.The extent of enhancement of IgE-mediated basophil de-granulation by GGA was mild compared to that by IL-3,and GGA did not show additive augmentation of histamine release by IL-3-treated basophils (Fig.1c).As shown in Figure 1d,another geranylgeranyl com-pound,geranylgeraniol (Sigma),also upregulated ba-sophil histamine release evoked by anti-IgE antibodyor PMA.On the other hand,compounds havingsmaller structures,such as geranylacetone and farne-sol,showed no effect on basophil degranulation (data not shown).Statins inhibit intracellular geranylger-anylation,resulting in suppression of the activation profiles of inflammatory cells,5-7and basophil de-granulation in response to anti-IgE antibody or PMA was significantly suppressed by preincubation with simvastatin at 50μM (Fig.1e).Geranylgeranyl compounds are reported to be in-volved in intracellular signal cascades in various cells,including mast cell activation evoked by IgE crosslinkage.5-7Our present finding that exogenously added GGA can enhance basophil activation suggests that GGA enters basophils and then behaves as a sub-strate in the cell activation pathway.Simvastatin,which can inhibit intracellular geranylgeranylation,suppressed basophil degranulation triggered by anti-IgE antibody and PMA,but not A23187.This finding coincides with our results that GGA augmented baso-phil degranulation evoked by anti-IgE antibody and PMA,but not A23187or MCP-1,suggesting that pro-tein kinase C or related molecule(s)may be the tar-get of GGA.It appears that geranyl and farnesyl com-pounds are not involved in the above pathway in ba-sophils.GGA’s various novel actions are being unveiled through recent experimental approaches.Mostly based on murine studies,this compound is able to suppress vicious inflammatory disorders of the skin or visceral organs,including pulmonary inflammation induced by gefitinib,an inhibitor of epidermal growth factor receptor-mediated signals.3It is thought that one of main in vivo effects of GGA is induction of tissue-stabilizing heat shock proteins.2,3In vivo stud-ies have so far tested GGA at μM to mM concentra-tions and have found increases in those proteins and changes in cell fate.8,9Our present findings suggest that GGA at relatively high concentrations can also exert acute effects on cellular functions and enhance the activation of basophils evoked by certain secre-tagogues.Although the in vivo significance of our findings and the whole aspect of the biologic actions of GGA remain unclear,elucidation of the precise roles of this compound in allergies and other tissue-damaging disorders is of special interest in light of its characteristic host-protecting properties.ACKNOWLEDGEMENTSThe authors thank Ms.Sayaka Igarashi for her excel-lent technical help.Yuko Nakase 1,Masao Yamaguchi 1,Naoya Sugimoto 1,Maho Suzukawa 2,Hidenori Arai 1,Hiroyuki Nagase 1and Ken Ohta 1,2Allergology International.2014;63(Suppl 1):49-51DOI:10.2332!allergolint.13-LE-0637Nakase Y et al.50Allergology International Vol 63,Suppl 1,2014www.jsaweb.jp !Fi g . 1 Mod u lation of b asophil histamine release b y geranylgeranyl and related compo u nds. (a ) Basophil preparations w ere preinc ub ated w ith and w itho u t GGA and then stim u lated w ith vario u s secretagog u es. GGA at 1.4 and 2.7 mM corresponds to 0.5 and 1 μl/ml, respectively. Histamine release w as expressed as a percentage of the total cell u lar histamine after s ub tracting spontaneo u s release (u s u ally <5%). Data are the mean ± SEM of three to six separate experiments. *p ≤ 0.05, vers u s corre-sponding val u es of cells not preinc ub ated w ith GGA. (b ) Baseline histamine release b y b asophils after treatment w ith GGA. Cells w ere preinc ub ated w ith GGA at 1 μl/ml for the indicated times, w ashed and then inc ub ated w itho u t any secretagog u e for 45 min. Data sho w n are representative of three separate experiments that generated similar res u lts. (c ) Priming effects of GGA and IL-3 on b asophil degran u lation. Cells w ere preinc ub ated w ith and w itho u t GGA for 15 min, w ashed and then inc ub ated w ith and w itho u t IL-3 b efore stim u lation w ith anti-IgE anti b ody. Data are the mean ± SEM (n = 3). *p < 0.05 vers u s corresponding val u e of cells not preinc ub ated w ith GGA. p < 0.05 vers u s corresponding val u e of IL-3-u ntreated cells. (d ) Effect of geranyl-geraniol on b asophil histamine release. The indicated concentration of this compo u nd (0.5 μl/ml, 1.5 mM) did not ind u ce non-specifi c histamine release. Data are the mean ± SEM (n = 3). *p < 0.05 vers u s corresponding val u e of cells not preinc ub ated w ith geranylgeraniol. (e ) Simvastatin s u ppressed b asophil degran u lation. Basophils w ere preinc ub ated w ith and w itho u t simvas-tatin for 15 min at 37˚C, w ashed and then stim u lated w ith anti-IgE anti b ody or P MA for 45 min. Data are the mean ± SEM (n = 4). *p < 0.05, vers u s corresponding val u e of cells u ntreated w ith simvastatin.100a 80604020010080604020GGA (mM) - 2.7 - 2.7 IL-3 (pM) - - 300 300 a nti-IgE (P g/ml) 1.4 141.4 141.4 14 1.4 141.414401000.10.210100PMA (ng/ml)Pretreatment with GGA GGA (-)GGA 1.4 mM GGA 2.7 mMA23187 (P g/ml)anti-IgE (P g/ml)MCP-1 (nM)H i s t a m i n e r e l e a s e (%)c H i s t a m i n e r e l e a s e (%)80604020e100806040200d H i s t a m i ne r e l e a s e (%)3020101.4141000.2MCP-1(nM)A23187(P g/ml)10anti-IgE (P g/ml)PMA(ng/ml)100Statin (P M)-50-501.4 14 1.4 1410 100anti-IgE (P g/ml)PMA (ng/ml)10 100515Pretreatment with GGA (min)Pretreatment withgeranylgeraniol 30(-)1.5 mM60120b B a s e l i n e h i s t a m i n e r e l e a s e (%)GGA Modulates Basophil ActivationAllergology International Vol 63,Suppl 1,2014www.jsaweb.jp !511Divisionof Respiratory Medicine and Allergology,Department of Medicine,Teikyo University School of Medicine and 2National Hospital Organization Tokyo National Hospital,Tokyo,Japan Email:myama@med.teikyo−u.ac.jpConflict of interest:No potential conflict of interest was disclosed.REFERENCES1.Karasuyama H,Mukai K,Obata K,Tsujimura Y,Wada T.Nonredundant roles of basophils in immunity.Annu Rev Immunol 2011;29:45-69.2.Ishihara T,Suemasu S,Asasno T,Tanaka K,Mizushima T.Stimulation of gastric ulcer healing by heat shock pro-tein 70.Biochem Pharmacol 2011;82:728-36.3.Namba T,Tanaka K,Hoshino T,Azuma A,Mizushima T.Suppression of expression of heat shock protein 70by ge-fitinib and its contribution to pulmonary fibrosis.PLoS One 2011;6:e27296.4.Koketsu R,Yamaguchi M,Suzukawa M et al .Pretreat-ment with low levels of Fc εRI-crosslinking stimulation en-hances basophil mediator release.Int Arch Allergy Immu-nol 2013;161:S23-31.5.Fujimoto M,Oka T,Murata T,Hori M,Ozaki H.Fluvasta-tin inhibits mast cell degranulation without changing the cytoplasmic Ca 2+level.Eur J Pharmacol 2009;602:432-8.6.Majlesi Y,Samorapoompichit P,Hauswirth AW et al .Cerivastatin and atorvastatin inhibit IL-3-dependent differ-entiation and IgE-mediated histamine release in human basophils and downmodulate expression of the basophil-activation antigen CD203c !E-NPP3.J Leukoc Biol 2003;73:107-17.7.Graham TE,Pfeiffer JR,Lee RJ et al .MEK and ERK acti-vation in ras-disabled RBL-2H3mast cells and novel roles for geranylgeranylated and farnesylated proteins in Fc εRI -mediated signaling.J Immunol 1998;161:6733-44.8.Endo S,Hiramatsu N,Hayakawa K et al .Geranylgerany-lacetone,an inducer of the 70-kDa heat shock protein (HSP70),elicits unfolded protein response and coordi-nates cellular fate independently of HSP70.Mol Pharma-col 2007;72:1337-48.9.Nanke Y,Kawamoto M,Yago T,Chiba J,Yamanaka H,Kotake S.Geranylgeranylacetone,a non-toxic inducer of heat shock protein,induces cell death in fibroblast-like synoviocytes from patients with rheumatoid arthritis.Mod Rheumatol 2009;19:379-83.。